Tenderwize
Retour à la recherche

Open-House non-exclusive rebate agreement for BeclometasonFormoterolGlycopyrronium

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jan 31, 2027 · 156 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff BeclometasonFormoterolGlycopyrronium (ATC-Code nach WHO: R03AL09)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Structured data says electronic submission is not allowed, while the notice text says communication and transmission oc...

Important participation documents are referenced but not fully provided in the extracted text, especially 'Anschreiben'...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2027
  • Non-exclusive supply/rebate agreement for pharmaceutical products containing BeclometasonFormoterolGlycopyrronium (ATC R03AL09).
  • Open-House model: contract conclusion is open to all interested companies during the participation period if they meet and accept the conditions.
Afficher le résumé complet

This is an Open-House pharmaceutical supply arrangement for the active substance BeclometasonFormoterolGlycopyrronium (ATC R03AL09) with AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet and accept the participation conditions. No contract value, minimum purchase volume, or guaranteed demand is stated. Participation documents are available via DTVP, but the extracted procurement documents were not provided for analysis, so document-based requirements may be incomplete.

Risques

Structured data says electronic submission is not allowed, while the notice text says communication and transmission oc...

Important participation documents are referenced but not fully provided in the extracted text, especially 'Anschreiben'...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • The bidder must submit the self-declaration on the absence of exclusion grounds under §§ 123, 124 GWB.

Administrative

  • The bidder must submit the self-declaration regarding EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576).

Critères d'attribution

Lot 1

No lot-specific award criteria stated; Open-House participation is based on meeting and accepting the stated conditions.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-House non-exclusive rebate agreement for BeclometasonFormoterolGlycopyrronium

Supply lot for a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V for the active substance BeclometasonFormoterolGlycopyrronium (ATC R03AL09). The arrangement is an Open-House model, so any interested pharmaceutical company meeting the conditions may participate. Place of performance is Dresden, Germany. Lot information comes from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jan 2025 - Jan 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No lot-specific award criteria stated; Open-House participation is based on meeting and accepting the stated conditions.

Date limite

Deadline Jan 31, 2027

Détails de la procédure

Date de publication
03 Dec 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
738758-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30